{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T13:35:11Z","timestamp":1778333711911,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1007\/s11864-006-0016-7","type":"journal-article","created":{"date-parts":[[2007,7,4]],"date-time":"2007-07-04T18:16:29Z","timestamp":1183572989000},"page":"237-245","source":"Crossref","is-referenced-by-count":14,"title":["Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance"],"prefix":"10.1007","volume":"7","author":[{"given":"Joan","family":"Blad\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"16_CR1","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","volume":"302","author":"RA Kyle","year":"1980","unstructured":"Kyle RA, Greipp PR: Smoldering multiple myeloma. N Engl J Med 1980, 302:1347\u20131349. SMM is first recognized and reported.","journal-title":"N Engl J Med"},{"key":"16_CR2","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/archinte.1988.00380090051014","volume":"148","author":"R Alexanian","year":"1988","unstructured":"Alexanian R, Barlogie B, Dixon D: Prognosis of asymp-tomatic multiple myeloma. Arch Intern Med 1988, 148:1963\u20131965. First study on prognostic factors in asymptomatic myeloma.","journal-title":"Arch Intern Med"},{"key":"16_CR3","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1600-0609.1991.tb01857.x","volume":"47","author":"F Wisloff","year":"1991","unstructured":"Wisloff F, Andersen P, Brandt E, et al.: Incidence and follow-up of asymptomatic multiple myeloma. Eur J Haematol 1991, 47:338\u201341.","journal-title":"Eur J Haematol"},{"key":"16_CR4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0002-9343(93)90120-E","volume":"94","author":"M Dimopoulos","year":"1993","unstructured":"Dimopoulos M, Moulopoulos A, Smith T, et al.: Risk of disease progression in asymptomatic multiple myeloma. Am J Med 1993, 94:57\u20131.","journal-title":"Am J Med"},{"key":"16_CR5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/ajh.2830480201","volume":"48","author":"T Facon","year":"1995","unstructured":"Facon T, Menard JF, Michaux JL, et al.: Prognostic factors in low tumor mass asymptomatic multiple myeloma: a report on 91 patients. Am J Hematol 1995, 48:71\u20135.","journal-title":"Am J Hematol"},{"key":"16_CR6","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1046\/j.1365-2141.1997.1122939.x","volume":"97","author":"D Weber","year":"1997","unstructured":"Weber D, Dimopoulos MA, Moulopoulos LA, et al.: Prog-nostic features of asymptomatic multiple myeloma. Br J Haematol 1997, 97:810\u201314.","journal-title":"Br J Haematol"},{"key":"16_CR7","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1200\/JCO.2002.20.6.1625","volume":"20","author":"C Cesana","year":"2002","unstructured":"Cesana C, Klersy C, Barbarano L, et al.: Prognostic factors for malignant transformation in monoclonal gammo-pathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol 2002, 20:1625\u2013634.","journal-title":"J Clin Oncol"},{"key":"16_CR8","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1046\/j.1365-2141.2003.04654.x","volume":"123","author":"Blad\u00e9 Rosi\u00f1ol","year":"2003","unstructured":"Rosi\u00f1ol Blad\u00e9, Esteve J, et al.: Smoldering multiple myeloma: natural history and recognition of an evolv-ing type. Br J Haematol 2003, 123:631\u201336. Natural history of SMM diagnosed according to stringent criteria of Kyle and Greipp [1] in a series of 53 patients. The evolving variant is first recognized.","journal-title":"Br J Haematol"},{"key":"16_CR9","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","volume":"121","author":"International Myeloma Working Group","year":"2003","unstructured":"International Myeloma Working Group: Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders. Br J Haematol 2003, 121:749\u201357. The new diagnostic criteria of SMM by the International Myeloma Working Group are reported.","journal-title":"Br J Haematol"},{"key":"16_CR10","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.1995.13.1.251","volume":"13","author":"LA Moulopoulos","year":"1995","unstructured":"Moulopoulos LA, Dimopoulos MA, Smith TL, et al.: Prognostic significance of magnetic resonance imag-ing in patients with asymptomatic multiple myeloma. J Clin Oncol 1995, 13:251\u201356. First report on the impact of MRI on the progression rate of asymptomatic myeloma.","journal-title":"J Clin Oncol"},{"key":"16_CR11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1148\/radiology.201.1.8816551","volume":"201","author":"BC Berg Van de","year":"1996","unstructured":"Van de Berg BC, Lecouvet FE, Michaux L, et al.: Stage I multiple myeloma: value of MRI of the bone marrow in the determination of prognosis. Radiology 1996, 201:243\u201346.","journal-title":"Radiology"},{"key":"16_CR12","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1046\/j.1365-2141.1999.01244.x","volume":"104","author":"X Mariette","year":"1999","unstructured":"Mariette X, Zagdanski AM, Guermazi A, et al.: Prognostic value of vertebral lesions detected by magnetic reso-nance imaging in patients with stage I multiple myeloma. Br J Haematol 1999, 104:723\u201329.","journal-title":"Br J Haematol"},{"key":"16_CR13","first-page":"687a","volume":"102","author":"M Wang","year":"2003","unstructured":"Wang M, Alexanian R, Delasalle K, Weber D: Abnormal MRI of spine is the dominant risk factor for early progression of asymptomatic myeloma. Blood 2003, 102: 687a.","journal-title":"Blood"},{"key":"16_CR14","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0025-6196(12)65066-6","volume":"62","author":"PR Greipp","year":"1987","unstructured":"Greipp PR, Witzig TE, Gonchoroff NJ, et al.: Immuno-fluorescence labeling index in multiple myeloma and related monoclonal gammopathies. Mayo Clin Proc 1987, 62:969\u201377.","journal-title":"Mayo Clin Proc"},{"key":"16_CR15","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1200\/JCO.1988.6.6.1041","volume":"6","author":"TE Witzig","year":"1988","unstructured":"Witzig TE, Gonchoroff NJ, Katzman JA, et al.: Peripheral blood B cell labeling indices are a measure of disease activity in patients with monoclonal gammopathies. J Clin Oncol 1988, 6:1041\u2013046.","journal-title":"J Clin Oncol"},{"key":"16_CR16","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2141.1994.tb04908.x","volume":"87","author":"TE Witzig","year":"1994","unstructured":"Witzig TE, Kyle RA, O`Fallon WM, Greipp PR: Detection of peripheral blood plasma cells as a predictor of disease course in patients with smoldering multiple myeloma. Br J Haematol 1994, 87:266\u201372.","journal-title":"Br J Haematol"},{"key":"16_CR17","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1365-2141.2005.05673.x","volume":"130","author":"Corri\u00f3 Bad\u00e9 Rosi\u00f1ol","year":"2005","unstructured":"Rosi\u00f1ol Corri\u00f3 Bad\u00e9, et al.: Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma. Br J Haematol 2005, 130:729\u201332.","journal-title":"Br J Haematol"},{"key":"16_CR18","doi-asserted-by":"crossref","first-page":"949a","DOI":"10.1182\/blood.V106.11.949.949","volume":"106","author":"RA Kyle","year":"2005","unstructured":"Kyle RA, Remstein E, Therneau T, et al.: The natural his-tory of smoldering (asymptomatic) multiple myeloma [abstract 3396]. Blood 2005, 106: 949a. First report on the natural history of SMM, diagnosed according to the new criteria proposed by the International Myeloma Working Group, in a series of 301 patients from the Mayo Clinic.","journal-title":"Blood"},{"key":"16_CR19","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/0002-9343(78)90522-3","volume":"64","author":"RA Kyle","year":"1978","unstructured":"Kyle RA: Monoclonal gammopathy of undetermined significance: natural history in 241 cases. Am J Med 1978, 64:814\u201326. The natural history of MGUS is first reported, and the term MGUS is coined.","journal-title":"Am J Med"},{"key":"16_CR20","first-page":"211","volume":"56","author":"J Waldesntr\u00f6m","year":"1961","unstructured":"Waldesntr\u00f6m J: Studies on conditions associated with disturbed gammaglobulin formation (gammopathies). Harvey Lect 1961, 56:211\u201331.","journal-title":"Harvey Lect"},{"key":"16_CR21","doi-asserted-by":"crossref","first-page":"934a","DOI":"10.1182\/blood-2003-01-0227","volume":"102","author":"RA Kyle","year":"2003","unstructured":"Kyle RA, Thernau TM, Rajkumar SV, et al.: Prevalence of monoclonal gammopathy of undetermined significance (MGUS) in Olmsted County, MN residents 50 years of age. Blood 2003, 102: 934a.","journal-title":"Blood"},{"key":"16_CR22","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1001\/jama.1984.03340380031018","volume":"251","author":"RA Kyle","year":"1984","unstructured":"Kyle RA: \u201cign\u2253noclonal gammopathy: a misno-mer. JAMA 1984, 251:1849\u2013854.","journal-title":"JAMA"},{"key":"16_CR23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0025-6196(12)60015-9","volume":"68","author":"RA Kyle","year":"1993","unstructured":"Kyle RA: \u201cign\u2253noclonal gammopathy--after 20-35 years of follow-up. Mayo Clin Proc 1993, 68:26\u20136.","journal-title":"Mayo Clin Proc"},{"key":"16_CR24","doi-asserted-by":"crossref","first-page":"859","DOI":"10.4065\/79.7.859","volume":"79","author":"RA Kyle","year":"2004","unstructured":"Kyle RA, Thernau TM, Rajkumar SV, et al.: Long-term follow-up of 241 patients with monoclonal gammo-pathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc 2004, 79:859\u201366.","journal-title":"Mayo Clin Proc"},{"key":"16_CR25","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000203676","volume":"97","author":"P Pasqualetti","year":"1997","unstructured":"Pasqualetti P, Festuccia V, Collacciani A, Casale R: The natural history of monoclonal gammopathy of unde-termined significance: a 5- to 20-year follow-up of 263 cases. Acta Haematol 1997, 97:174\u201379.","journal-title":"Acta Haematol"},{"key":"16_CR26","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","volume":"346","author":"RA Kyle","year":"2002","unstructured":"Kyle RA, Thernau TM, Rajkumar SV, et al.: A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002, 346:564\u201369. Report on prognostic features in the largest series (1384 patients) with longest follow-up published so far.","journal-title":"N Engl J Med"},{"key":"16_CR27","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJM200206273462614","volume":"346","author":"S Montoto","year":"2002","unstructured":"Montoto S, Blad\u00e9 J, Montserrat E: Monoclonal gammo-pathy of undetermined significance [letter to the editor]. N Engl J Med 2002, 346:2087\u2013088.","journal-title":"N Engl J Med"},{"key":"16_CR28","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1182\/blood.V87.3.912.bloodjournal873912","volume":"87","author":"L Baldini","year":"1996","unstructured":"Baldini L, Guffanti A, Cesana BM, et al.: Role of differ-ent hematologic variables in defining the risk of malignant transformation in monoclonal gammo-pathy. Blood 1996, 87:912\u201318.","journal-title":"Blood"},{"key":"16_CR29","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2141.1992.tb08245.x","volume":"81","author":"L\u00f3pez Gulermo A Blad\u00e9","year":"1992","unstructured":"Blad\u00e9, L\u00f3pez Gulermo A, Rozman C, et al.: Malignant transformation and life expectancy in monoclonal gam-mopathy of undetermined significance. Br J Haematol 1992, 81: 391\u201394.","journal-title":"Br J Haematol"},{"key":"16_CR30","first-page":"1172","volume":"86","author":"H Gregersen","year":"2001","unstructured":"Gregersen H, Mellemkjaer L, Ibsen JS, et al.: The impact of M-component type and immunoglobulin concen-tration on the risk of malignant transformation in patients with monoclonal gammopathy of undeter-mined significance. Haematologica 2001, 86:1172\u2013179.","journal-title":"Haematologica"},{"key":"16_CR31","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","volume":"106","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar SV, Kyle RA, Therneau TM, et al.: Serum free light chain ratio is an independent risk factor for pro-gression in monoclonal gammopathy of undetermined significance. Blood 2005, 106:812\u201317. Two MGUS populations with a highly different risk of malignant transformation at 20 years of follow-up are clearly identified.","journal-title":"Blood"},{"key":"16_CR32","doi-asserted-by":"crossref","first-page":"5668","DOI":"10.1200\/JCO.2005.03.159","volume":"23","author":"S Kumar","year":"2005","unstructured":"Kumar S, Rajkumar SV, Kyle RA, et al.: Prognostic value of circulating plasma cells in monoclonal gammo-pathy of undetermined significance. J Clin Oncol 2005, 23:5668\u2013674.","journal-title":"J Clin Oncol"},{"key":"16_CR33","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0609.1993.tb00148.x","volume":"50","author":"M Hjorth","year":"1993","unstructured":"Hjorth M, Hellquist I, Holmberg E, et al.: Initial versus deferred melphalan-prednisone therapy for asymp-tomatic multiple myeloma stage I--a randomized study. Eur J Haematol 1993, 50:95\u201302. Randomized trial showing no benefit of early versus deferred therapy in patients with asymptomatic stage IA myeloma.","journal-title":"Eur J Haematol"},{"key":"16_CR34","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/bjc.1996.212","volume":"73","author":"G Grignani","year":"1996","unstructured":"Grignani G, Gobbi P, Formisano R, et al.: A prognostic index for multiple myeloma. Br J Cancer 1996, 73:1101\u2013107.","journal-title":"Br J Cancer"},{"key":"16_CR35","first-page":"3111","volume":"6","author":"SV Rajkumar","year":"2000","unstructured":"Rajkumar SV, Leong T, Roche PC, et al.: Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000, 6:3111\u2013116.","journal-title":"Clin Cancer Res"},{"key":"16_CR36","first-page":"2210","volume":"8","author":"SV Rajkumar","year":"2002","unstructured":"Rajkumar SV, Mesa RA, Fonseca R, et al.: Bone marrow angiogenesis in 400 patients with monoclonal gammo-pathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002, 8:2210\u2013216.","journal-title":"Clin Cancer Res"},{"key":"16_CR37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/ajh.2830500103","volume":"50","author":"A Vacca","year":"1995","unstructured":"Vacca A, Di Loreto M, Ribatti D, et al.: Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-I, VLA-4, LAM-1, and CD 34. Am J Hematol 1995, 50:9\u201314.","journal-title":"Am J Hematol"},{"key":"16_CR38","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R, et al.: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341:1565\u2013571. First report on the efficacy of thalidomide in a large series of patients with relapsed and refractory MM.","journal-title":"N Engl J Med"},{"key":"16_CR39","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V98.2.492","volume":"98","author":"B Barlogie","year":"2001","unstructured":"Barlogie B, Desikan R, Eddlemon P, et al.: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prog-nostic factors in a phase 2 study of 169 patients. Blood 2001, 98:492\u201394.","journal-title":"Blood"},{"key":"16_CR40","first-page":"832","volume":"89","author":"Cibeira MT Rosi\u00f1ol","year":"2004","unstructured":"Rosi\u00f1ol Cibeira MT, Blad\u00e9, et al.: Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica 2004, 89:832\u201335. Report confirming the lack of efficacy of thalidomide on soft-tissue plasmacytomas, suggesting that the homing of tumor cells in the bone marrow is crucial for the antimyeloma effect of thalidomide.","journal-title":"Haematologica"},{"key":"16_CR41","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/sj.leu.2402866","volume":"17","author":"SV Rajkumar","year":"2003","unstructured":"Rajkumar SV, Gertz MA, Lacy MQ, et al.: Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003, 17:775\u201379. Report on the effect of thalidomide in SMM.","journal-title":"Leukemia"},{"key":"16_CR42","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","volume":"21","author":"D Weber","year":"2003","unstructured":"Weber D, Rankin K, Gavino M, et al.: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003, 21: 16\u20139. Report on the effect of thalidomide in SMM.","journal-title":"J Clin Oncol"},{"key":"16_CR43","doi-asserted-by":"crossref","first-page":"721a","DOI":"10.1182\/blood-2004-12-4617","volume":"106","author":"JA Lust","year":"2005","unstructured":"Lust JA, Lacy MQ, Zeldenrust SR, et al.: In smoldering\/indolent myeloma patients treated with interleukin-1 receptor antagonist (IL-1Ra), responders demonstrate a significantly increased time to progression and decreased C-reactive protein (CRP) compared with non-responders [abstract 2567]. Blood 2005, 106: 721a.","journal-title":"Blood"},{"key":"16_CR44","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1046\/j.1365-2141.1998.00976.x","volume":"103","author":"M Dhodapkar","year":"1998","unstructured":"Dhodapkar M, Singh J, Mehta J, et al.: Anti-myeloma activity of pamidronate in vivo. Br J Haematol 1998, 103: 530\u201332.","journal-title":"Br J Haematol"},{"key":"16_CR45","first-page":"759","volume":"84","author":"A Corso","year":"1999","unstructured":"Corso A, Astori C, Orlandi E, et al.: Transient response of myeloma clone to pamidronate therapy. Haemato-logica 1999, 84:759\u201360.","journal-title":"Haemato-logica"},{"key":"16_CR46","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1046\/j.1365-2141.2002.03549.x","volume":"118","author":"A Martin","year":"2002","unstructured":"Martin A, Gac\u00eda sanz R Hern\u00e1dez J, et al.: Pamidronate induces bone formation in patients with smoldering or indolent myeloma, with no significant anti-tumour effect. Br J Haematol 2002, 118:239\u201343.","journal-title":"Br J Haematol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-006-0016-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-006-0016-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-006-0016-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T01:25:08Z","timestamp":1587691508000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-006-0016-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["16"],"URL":"https:\/\/doi.org\/10.1007\/s11864-006-0016-7","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}